id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
3198465,9f6c2941-f6bb-4b8e-8133-4c462f5823e0,3T,"BARKER LEAVITT, PLLC (SKA MR. JAMES C. BARKER)",292538,SONIC HEALTHCARE USA,2024,third_quarter,MED,"Issues relating to the regulation of laboratory developed tests, the VALID Act, issues relating to PAMA (the SALSA Bill), federal policies relating to the implementation of the anti-kickback requirements of the Support for Patients and Communities Act. Physician Lab Fee schedule. Anatomic Fee Schedule and Surprise Billing. COVID Testing and billing procedures. COVID Vaccine Federal Mandate.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2024-07-18T11:27:57-04:00
3231516,c6b8757f-ac1a-469c-a23c-566a013a1d50,Q3,"HELIX, INC.",401106164,"HELIX, INC.",2024,third_quarter,MED,"Oversight of Lab Developed Tests, express legislative authority. Expanded access to VAMC genetic and pharmacogemomic testing","HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,80000,0,0,2024-09-30T10:22:47-04:00
3231552,c7621dd5-467c-4527-9241-b3a4d0037ca9,Q3,"AUBURN HEALTH STRATEGIES, LLC",292697,AMERICAN PROFICIENCY INSTITUTE,2024,third_quarter,MED,proficiency testing for clinical laboratories,SENATE,,,0,0,2024-09-30T14:58:02-04:00
3231772,1ab267ff-7ee9-4374-b85b-53b2fbab81ea,Q3,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2024,third_quarter,MED,Funding for USDA ARS human nutrition research in the FY2025 House and Senate Agriculture appropriation bills.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-01T16:20:09-04:00
3231947,d8143dc3-1f32-4e0c-82e5-b4d6709c0fff,Q3,"MAGILL ASSOCIATES, LLC",401103511,THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES,2024,third_quarter,MED,FY 2025 appropriations for the development of a synthetic vaccine,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-02T11:25:44-04:00
3231998,f3bbb9cd-039b-45b0-b193-b5a4e5c2e3b9,Q3,"HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC.",52925,"HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC.",2024,third_quarter,MED,HR 4534/S 2245 - Women and Lung Cancer Research and Preventative Services Act of 2023 All provisions This bill requires a review of women and lung cancer.,"HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-10-02T12:31:24-04:00
3232044,3d4d3fa4-784b-4cbe-9d9d-47aed4666d31,Q3,FLORIDA STATE UNIVERSITY,14952,FLORIDA STATE UNIVERSITY,2024,third_quarter,MED,FY 2025 Labor HHS Education Appropriations Act - NIH (NINDS),"HOUSE OF REPRESENTATIVES,SENATE",,38000,0,0,2024-10-02T14:25:32-04:00
3232106,5fc1df71-9268-4dc6-8341-726e03734bf0,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2024,third_quarter,MED,Monitor Health Data Policy.,"Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-02T16:03:39-04:00
3232209,43bb3a80-80bd-4ba6-8aa2-00d2bdb19c60,Q3,WATKINS & EAGER PLLC,401104403,NATIONAL FRAGILE X FOUNDATION,2024,third_quarter,MED,Assist in matters necessary for Advocacy Day planning on The Hill; Arrange meetings and appointments for NFXF officials; Work to encourage Members to act favorably on matters of interest and benefit to NFXF; Encourage Members to meet with constituents impacted by Fragile X.,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2024-10-03T10:39:46-04:00
3232234,41da2eef-7e12-4553-98b8-76dbc47f668c,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2024,third_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2024-10-03T11:00:22-04:00
3232244,d398a8c7-7a25-4d73-9ede-b1542fc8a84a,Q3,MARSHFIELD CLINIC HEALTH SYSTEM,57830,MARSHFIELD CLINIC HEALTH SYSTEM,2024,third_quarter,MED,"research support, agriculture, farm safety, child care and agriculture communities","HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-10-03T11:05:37-04:00
3232263,a3049516-3add-45b9-8719-58d8f411e166,Q3,THE HARRIS FIRM,68376,HOLISTIC INDUSTRIES INC.,2024,third_quarter,MED,Issues pertaining to cannabis CSA scheduling.,"Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",50000,,0,0,2024-10-03T11:16:10-04:00
3232272,07e35fc5-cc41-4f4b-a05e-fd4c872a2c94,Q3,THE NEW ENGLAND COUNCIL,29106,NEW ENGLAND COUNCIL,2024,third_quarter,MED,HR 5539 - Optimizing Research Progress Hope and New Cures Act (OPRHAN Cures Act),HOUSE OF REPRESENTATIVES,,5000,0,0,2024-10-03T11:30:42-04:00
3232328,af041761-8026-4e75-b1ca-177410fb53a3,Q3,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2024,third_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-03T14:02:34-04:00
3232347,f4755106-b877-432a-9bf4-527b35c00c3a,Q3,DREXEL UNIVERSITY,40032273,DREXEL UNIVERSITY,2024,third_quarter,MED,Advocacy around Medicaid reimbursements for high Medicaid medical facilities,"HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2024-10-03T15:09:04-04:00
3232405,dd0f4f46-dcce-4e2e-87e7-fb9ecb0a5bca,Q3,2359 STRATEGIES,401106114,TRAVERE THERAPEUTICS,2024,third_quarter,MED,Rare kidney disease,"HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2024-10-03T18:25:31-04:00
3232469,2d947b19-76b0-43b8-921b-17d69a18a241,Q3,"FRANCIS EDWARD & CRONIN, INC.",311314,CURE ALZHEIMER'S FUND,2024,third_quarter,MED,Legislation related to Alzheimer's disease research,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2024-10-04T09:39:28-04:00
3232904,83670047-0f44-4a43-918b-22dd6caed2d1,Q3,"MASON STREET CONSULTING, LLC",401105150,PERIMETER MEDICAL IMAGING,2024,third_quarter,MED,Advanced Research Projects Agency for Health (ARPA-H).,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-07T06:23:28-04:00
3233113,a5007714-6789-4c90-95cc-65b6057fa8e2,Q3,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",401103161,"UNIVERSITY OF MARYLAND, BALTIMORE (UMB)",2024,third_quarter,MED,NONE,,,10000,0,0,2024-10-07T12:58:29-04:00
3234012,4f29570d-925c-42b5-bceb-e72057c0ae73,Q3,IMPACT MANAGEMENT GROUP,401104137,ARKANSAS RESEARCH ALLIANCE,2024,third_quarter,MED,On behalf of client support continued and future funding for clinical research programs in Arkansas,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-09T10:13:57-04:00
3234120,935c6b78-3abe-47a5-b3ab-a4b2e949bf7b,Q3,IMPACT MANAGEMENT GROUP,401104137,"CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE, INC.",2024,third_quarter,MED,Supporting the passage of H.R. 3173 - Improving Seniors' Timely Access to Care Act of 2021,HOUSE OF REPRESENTATIVES,,,0,0,2024-10-09T12:11:34-04:00
3234268,46072976-131e-4f07-8ec4-cb42780296db,Q3,"COMPASS GOVERNMENT RELATIONS PARTNERS, LLC",401106533,"COALITION FOR INNOVATIVE LABORATORY TESTING, INC.",2024,third_quarter,MED,Matters pertaining to the VALID Act of 2023 (H.R.2369); Provisions that negatively impact Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory businesses; Docket No. FDA-2023-N-2177 (FDA's release of the Final Rule on LDTs,,,,0,0,2024-10-09T14:49:38-04:00
3234776,f1f0014b-f661-46e9-88d4-fde4f5543f81,Q3,"OLD NORTH STRATEGIES, LLC",401106174,"EXELA PHARMA SCIENCES, LLC",2024,third_quarter,MED,supply chain & FDA issues,"HOUSE OF REPRESENTATIVES,SENATE",108000,,0,0,2024-10-10T12:37:01-04:00
3234832,ebf75395-0eb2-493f-a5c3-58d8dce43c83,Q3,"MANATT, PHELPS, AND PHILLIPS",23645,LOMA LINDA UNIVERSITY MEDICAL CENTER,2024,third_quarter,MED,"Healthcare, Legislation Impacting Hospitals, Federal Funding/CPF and CDF",,140000,,0,0,2024-10-10T13:47:04-04:00
3234837,a45d2e79-f00b-4bcb-8a32-b583d2dccd5a,Q3,"MANATT, PHELPS, AND PHILLIPS",23645,MEDISYS HEALTH NETWORK,2024,third_quarter,MED,Provider Relief and COVID funding and other healthcare issues; Community Project Funding,,40000,,0,0,2024-10-10T13:48:02-04:00
3234927,5629b4f0-dd87-41b6-ae74-fb246aa7e502,Q3,BEN BARNES GROUP LP,5415,HUNTSMAN CORPORATION,2024,third_quarter,MED,CMS Medicare,"HOUSE OF REPRESENTATIVES,SENATE",18750,,0,0,2024-10-10T14:21:00-04:00
3234966,91e0fe40-acfb-4953-94c5-06380e72aad4,Q3,BEN BARNES GROUP LP,5415,"CLENE NANOMEDICINE, INC.",2024,third_quarter,MED,ALS,"HOUSE OF REPRESENTATIVES,SENATE",150000,,0,0,2024-10-10T14:35:12-04:00
3235255,2e0c20ad-5639-46ec-acd5-dc1005bbcf36,Q3,"THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA)",2970,"THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA)",2024,third_quarter,MED,none,,,189000,0,0,2024-10-11T10:56:11-04:00
3235284,1ac1d82e-e157-4cf1-90c6-d90f4200468e,Q3,SQUIRE PATTON BOGGS,30906,ALLIANCE FOR BIOSECURITY,2024,third_quarter,MED,Preparedness and response as it relates to Biosecurity.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-11T11:11:34-04:00
3235691,b80e0033-79f6-4941-94ca-0010175f1419,Q3,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2024,third_quarter,MED,"Advocated for increased FY25 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY25 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for at least $10.5 billion for HRSA programs in the FY 2025 Labor, Health and Human Services, Education, and Related Agencies appropriations bill. Advocated for passage of H.R. 7050 - the Substance Use Disorder Workforce Act of 2024, with a recommendation that the Senate include additional monetary incentives in the bill for physicians training as addiction specialists. Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use. Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for the Residential Recovery for Seniors Act (H.R. 9232 / S. 4860). This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Advocated for various substance use disorder workforce and coverage policy changes, including the SUPPORT for Patients and Communities Reauthorization Act (S. 3393). Advocated for certain annual increases for Medicare office based SUD bundled codes. Advocated for H.R.5163/S. 3193 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment. Advocated for S. 3145 - the Improving Access to Addiction Medicine Providers Act, legislation that would modernize the SAMHSA's Minority Fellowship Program (MFP) by amending the Public Health Service Act to include the field of addiction medicine in MFP. Supported the Medicaid Bump Act of 2024 (H.R. 4892/S. 3921). This legislation would incentivize states to expand coverage of mental health and substance use disorder (MH/SUD) services by providing a corresponding increase in the Federal Medical Assistance Percentage (FMAP) matching rate to 90 percent. Supported calls for the Biden Administration to rescind a $75 'cap' per patient per budget year on incentives in contingency management for treating stimulant use disorder. Advocated for the finalization of a DOJ/DEA rule to preserve the COVID 19 telemedicine initiation flexibilities for buprenorphine for OUD. Joined coalition letter recommending that CMS finalize a proposal to narrow Medicares in-custody definition to no longer include individuals on bail, parole, probation, and home detention. Joined coalition letter expressing support of proposed CMS actions to address Conditions of Participation for hospitals and critical access hospitals (CAHs) to improve maternal health outcomes. The letter requested that CMS expand the proposals to include substance use-related maternal health needs, recognizing that overdose is now a leading cause of maternal mortality. Submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on proposed changes to enhance access to substance use disorder (SUD) and mental health treatment. In prepared comments, ASAM recommended revisions to proposed digital mental health treatment codes, adoption of payment/coverage of intensive outpatient (IOP) treatment in standalone settings, and welcomed a proposal to allow people on bail, parole, probation, home detention, or in halfway houses to qualify for Medicare coverage. Submitted comment letter to the Drug Enforcement Administration (DEA) on a proposed rule that if finalized, would move marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Worked on and supported HR 9886/S 5271, the Broadening Utilization of Proven and Effective Treatment for Recovery Act or the BUPE for Recovery Act, which would require the Administrator of the Drug Enforcement Administration (DEA) to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency.","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,60000,0,0,2024-10-11T16:33:59-04:00
3235963,64d5163a-6881-4de7-8d71-b89588a2dfff,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,HAZELDEN BETTY FORD FOUNDATION,2024,third_quarter,MED,Educate key government stakeholders on Hazelden Betty Ford Foundation activities in support of substance use and mental health for US Service members and Veterans.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-12T15:50:14-04:00
3236059,22cae3fb-6835-4a33-9da9-0bac3ff3ac86,Q3,TIBER CREEK GROUP,20744,JAZZ PHARMACEUTICALS,2024,third_quarter,MED,Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-13T10:58:51-04:00
3236567,1deaf557-3149-4a0f-913d-34dc8a867294,Q3,CHAMBER HILL STRATEGIES,400645947,SANFORD HEALTH,2024,third_quarter,MED,"Issues impacting diagnostics including FDA regulation of laboratory developed tests; H.R.2369, VALID Act of 2023.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-14T11:50:38-04:00
3236590,532d7c3f-36b8-4e88-86f2-bbfe95f3eb9e,Q3,CHAMBER HILL STRATEGIES,400645947,"MAYO COLLABORATIVE SERVICES, INC.",2024,third_quarter,MED,"Issues impacting diagnostics including FDA regulation of laboratory developed tests; H.R.2369, the VALID Act of 2023; S. 1000/H.R. 2377, the Saving Access to Laboratory Services Act","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-14T12:03:39-04:00
3236811,339d5eb2-2660-4475-a5f3-f5e54f52cb9e,Q3,MCDERMOTT+ LLC,401103287,VERILY LIFE SCIENCES LLC,2024,third_quarter,MED,"Efforts relating to artificial intelligence, wastewater surveillance and drug and device innovation.","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-14T13:35:20-04:00
3236916,291b2137-1a0e-4f60-b556-0c3cf35a00ed,Q3,THE DLM GROUP,313794,"GENESIS HEALTH CARE, INC.",2024,third_quarter,MED,no activity,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-14T14:09:00-04:00
3236931,64573020-0b24-4600-8b2f-80ecb8e3536c,Q3,WINNING STRATEGIES WASHINGTON,50796,DIABETES PATIENT ADVOCACY COALITION,2024,third_quarter,MED,Issues related to treatment of diabetes and support for diabetes patients,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-14T14:11:06-04:00
3236982,59db301a-a355-4c47-8a5f-558511ca71f8,Q3,WINNING STRATEGIES WASHINGTON,50796,I AM ALS,2024,third_quarter,MED,"Funding for ALS research in annual Defense, Ag, and Labor-HHS-Education Appropriations bills","Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2024-10-14T14:31:59-04:00
3237025,e7da9a39-e368-4e17-8d77-ba84853b14b2,Q3,RESOLUTE-DC,401106654,MODEL MEDICINES,2024,third_quarter,MED,"Introduce Model Medicines and how the company is innovating at the intersection of data science, biology and drug development.","Health & Human Services, Dept of (HHS)",,,0,0,2024-10-14T14:53:18-04:00
3237179,998537b2-7dbf-422e-98c1-505aa5b36da1,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,ADVANCED MEDICAL TECHNOLOGY ASSOCIATION,2024,third_quarter,MED,Congressional outreach related to health care issues.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-14T15:45:34-04:00
3237202,87f99668-72fa-44a7-a2c9-37f2815008d0,Q3,"EFB ADVOCACY, LLC",401104430,UNITED FOR MEDICAL RESEARCH,2024,third_quarter,MED,Funding Issues related to the National Institutes of Health,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-14T15:52:39-04:00
3237270,f62f9a69-53f5-428b-b328-0b92ff535246,Q3,SQUIRE PATTON BOGGS,30906,"LA MAESTRA FOUNDATION ON BEHALF OF LA MAESTRA FAMILY CLINIC, INC.",2024,third_quarter,MED,Funding support for federally qualified health centers; reauthorization of programs,,20000,,0,0,2024-10-14T16:11:58-04:00
3237357,7bc28c7c-692a-48d0-9e77-cd83b9927d2f,Q3,"THE PETRIZZO GROUP, INC.",305932,SEATTLE CHILDREN'S HOSPITAL RESEARCH AND FOUNDATION,2024,third_quarter,MED,Increased funding for pediatric medical research,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2024-10-14T18:58:13-04:00
3237367,9791cc6f-651c-4483-998c-77cdae2c20a8,Q3,"THE PETRIZZO GROUP, INC.",305932,DYSAUTONOMIA INTERNATIONAL,2024,third_quarter,MED,"Advocate for NIH research funding for dysautonomia disorders, specifically Postural Orthostatic Tachycardia Syndrome (POTS) and funding to examine the correlation between POTS and Long COVID. Supporting establishment of an infection associated chronic conditions office at the NIH to coordinate research. Asking for continued support for the Autonomic Medicine Section at the NIH.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2024-10-14T19:07:56-04:00
3237377,4b3f358f-b58d-4b43-8fbe-522fe90c2fc8,Q3,"THE PETRIZZO GROUP, INC.",305932,OMEROS CORPORATION,2024,third_quarter,MED,"Development and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. FDA Rare Disease Center of Excellence","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2024-10-14T19:25:01-04:00
3237460,37cf3fb0-fe3e-4a61-a106-135e772ed277,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,MMV MEDICINES FOR MALARIA VENTURE,2024,third_quarter,MED,The purpose was to increase funding for malaria research in the Department of Defense.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-14T22:22:22-04:00
3237497,5a4e667d-0b32-45d4-ac28-97a4d5f9e285,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"ADVANCED MATERIALS AND DEVICES, INC.",2024,third_quarter,MED,Educated key government stakeholders on AMADs products applicable to the military and supported appropriations requests.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-14T23:45:11-04:00
3237677,103950fd-0c0f-46f7-91ab-e7d2171a5866,Q3,AMERICAN LUNG ASSOCIATION,2811,AMERICAN LUNG ASSOCIATION,2024,third_quarter,MED,"Issues relating to the Presidents FY25 budget; Issues relating to FY25 appropriations; Issues relating to the Presidents FY26 budget; Issues related to asthma, COPD, influenza, lung cancer, pneumonia, pulmonary fibrosis, tuberculosis and other lung diseases; Issues related to NIH reorganization; Issues related to lung disease treatment, prevention and research; Issues related to COVID-19; Issues related to telehealth; Issues related to infrastructure; Issues related to supplemental oxygen; Issues related to health equity; Issues related to Cancer Moonshot; Issues related to CDC public health workforce and data modernization; Issues related to regulatory reform; H.R. 833 Stop the Wait Act; Issues related to Medicaid; ; HR 890 The Guidance Out of Darkness Act; S 791 The Guidance Out of Darkness Act;; HR 357 Ensuring Accountability in Agency Rulemaking; ; HR 7867 Renewing Efficiency in Government by Budgeting Act; HR 115 Midnight Rules Relief Act; HR 1602, Health Care Affordability Act of 2023; S. 8 Improving Health Insurance Affordability Act of 2023; HR 9029 Departments of Labor, Health and Human Services, and Education and Related Agencies Appropriations Act, 2025; H.R. 8774 Department of Defense Appropriations Act 2025; S. 4942 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; S 4921 Department of Defense Appropriations Act 2025; HR 890 Guidance out of Regulatory Darkness Act; HR 9747 Continuing Appropriations and Extensions Act, 2025; HR 9494 Continuing Appropriations and Other Matters Act 2025; H.R. 9774, Health Care Affordability Act of 2024; S. 5194, Health Care Affordability Act of 2024; S. 652 Safe Step Act; HR 2630 Safe Step Act","Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,180000,0,0,2024-10-15T10:11:05-04:00
3237685,869ca243-93d5-4112-9755-18256575ec28,Q3,MCCARTHY STRATEGIC SOLUTIONS,300936,"INOTIV, INC.",2024,third_quarter,MED,"Animal research models to biopharmaceuticals, academic and government research for realizing life saving medications","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-15T10:12:15-04:00
3238202,db1e283b-cdd5-4e42-8415-34ceadd908be,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM,2024,third_quarter,MED,Educated key government stakeholders on the Medical Technology Enterprise Consortiums activities and partnership model in support of Servicemember health and readiness.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-15T13:06:53-04:00
3238250,67378b31-44e6-4ec1-98d0-62820146f642,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"NIRSENSE, LLC (FKA BIONICA LABS)",2024,third_quarter,MED,Educated key government stakeholders on NIRSenses activities and technologies in support of the Armed Forces and support Defense appropriations and authorization requests.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-15T13:22:31-04:00
3238500,4ccb9f79-c760-4110-bec7-26534d9f0797,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,SMITH & NEPHEW,2024,third_quarter,MED,Educated key government stakeholders on Smith+Nephew products applicable to the military and support appropriations requests.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-15T14:36:41-04:00
3238584,1ae66ac1-77ed-409b-825f-b232ae479143,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE GENEVA FOUNDATION,2024,third_quarter,MED,Educated key government stakeholders on The Geneva Foundations research and development activities in support of US Service members.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-15T14:53:21-04:00
3239075,5e50836f-7f39-4eb3-b4d8-251d03179838,Q3,"F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES",18411,F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES,2024,third_quarter,MED,"Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and H.R. 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 FY25 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act","HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2024-10-15T17:12:41-04:00
3239197,8daa35e6-f177-414e-bbea-c5f891e0aa1e,Q3,MICHAEL N. MCCARTY LAW OFFICE PLLC,401104300,AMERICAN MEDICAL TECHNOLOGISTS,2024,third_quarter,MED,"Legislation to regulate laboratory-developed in vitro diagnostic (IVD) tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369); support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to the Medical Laboratory Personnel Shortage Relief Act of 2024 (H.R.9849); support the Freedom to Invest in Tomorrow's Workforce Act (S. 722/H.R. 1477).","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-15T18:32:32-04:00
3239428,357558ac-418c-4423-9088-97067e3ebbae,Q3,VENABLE LLP,39941,AMERICAN SOCIETY OF TROPICAL MEDICINE AND HYGIENE,2024,third_quarter,MED,"Senate Malaria and National Tropical Diseases (NTD) Caucus H. Res 126 /S. Res 264 Supporting US role in Gavi, The Vaccine Alliance NIH reform proposals","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-16T09:25:56-04:00
3239443,cde3b0b3-4766-484e-b98e-c1227cf8c85a,Q3,FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC),86196,"INTUITIVE SURGICAL, INC.",2024,third_quarter,MED,Lobbying related to health care issues.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-16T09:34:02-04:00
3239490,37a1cfa6-d120-4b43-a69e-5b99aab72075,Q3,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2024,third_quarter,MED,N.A.,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2024-10-16T09:47:58-04:00
3239642,ec1641e6-47ed-4b96-9371-5ea3be5c49a9,Q3,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),1466,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),2024,third_quarter,MED,"* On July 7, ADLM joined with other healthcare providers in supporting a resolution to employ the Congressional Review Act as it pertains to the FDAs Proposed Rule, Docket No. FDA-2023-N-2177, Medical Devices: Laboratory Developed Tests. * On September 5, ADLM wrote to House and Senate leaders providing survey results indicating the clinical laboratories will have problems complying with the FDA final rule regulating LDTs. * On August 15 and September 4, ADLM initiated grassroots campaigns urging House and Senate members to support future legislative efforts to revoke the FDA LDT final rule. * On September 10th, ADLM participating in Rare Disease Congress Caucus outlining concern about FDA LDT final rule.","HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2024-10-16T10:32:59-04:00
3239671,8af3987b-07b1-47cd-a274-3b11239cea3a,Q3,COVINGTON & BURLING LLP,11195,AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA),2024,third_quarter,MED,Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation; VALID Act (H.R. 2369),SENATE,40000,,0,0,2024-10-16T10:39:44-04:00
3239892,a92a8c72-7bbf-40a1-bfe4-795cb990c326,Q3,COMMONWEALTH POLICY SOLUTIONS,401105004,RARE ACCESS ACTION PROJECT,2024,third_quarter,MED,Medicare and Medicaid rare diseases,"HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2024-10-16T11:42:12-04:00
3240080,5899d7a1-40cc-4102-996a-d54b8e74f6b7,Q3,STANFORD UNIVERSITY,36492,STANFORD UNIVERSITY,2024,third_quarter,MED,HR 2389 Resident Physician Shortage Reduction Act of 2023 Antiviral drug research / Antiviral Drug Discovery Centers,"HOUSE OF REPRESENTATIVES,SENATE",,110000,0,0,2024-10-16T12:16:34-04:00
3240168,13bdd63f-cd4d-4164-b4dd-f1d9be5f59e4,Q3,"PONTIS PARTNERS, LLC",401107566,KIDNEY TRANSPLANT COLLABORATIVE,2024,third_quarter,MED,Enactment of The Living Organ Volunteer Engagement (LOVE) Act,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-16T12:39:50-04:00
3240522,313f4c56-5088-4dd1-ab61-5ffe59dad829,Q3,O'NEILL AND ASSOCIATES,73134,"POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN)",2024,third_quarter,MED,"Healthcare, Medical","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2024-10-16T14:15:03-04:00
3240700,e6ed3c05-ce0d-4583-beeb-b5712de57291,Q3,O'NEILL AND ASSOCIATES,73134,CARIBBEAN CONNECTIONS EQUITABLE RESEARCH,2024,third_quarter,MED,Funding,"HOUSE OF REPRESENTATIVES,SENATE",25500,,0,0,2024-10-16T14:47:59-04:00
3240806,d846e581-f005-4215-828a-d318a6c3bcc4,Q3,"THE LIVINGSTON GROUP, LLC",49635,INNOVATIVE VACCINE TECHNOLOGIES,2024,third_quarter,MED,FY2025 appropriations for the development of a synthetic vaccine,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-16T15:10:02-04:00
3241117,b567681d-f194-47eb-b93f-a80faad037c4,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"THERADAPTIVE, INC.",2024,third_quarter,MED,Educated key government stakeholders on Theradaptives products applicable to the military and support appropriations requests.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-16T16:01:22-04:00
3241291,e160f404-86c8-4e9a-86d1-1f4db4e84c29,Q3,NATIONAL MULTIPLE SCLEROSIS SOCIETY,69674,NATIONAL MULTIPLE SCLEROSIS SOCIETY,2024,third_quarter,MED,"S.79 - Interagency Patent Coordination and Improvement Act of 2023, support passage S.113, the Prescription Pricing for the People Act of 2023,support passage S.142, the Preserve Access to Affordable Generics and Biosimilars Act, support passage S.148, the Stop Stalling Act, support passage S.150, the Affordable Prescriptions for Patients Act of 2023, support passage H.R.1114- Long COVID Recovery Now Act S.801/H.S. 1616 CARE for Long COVID Act, support passage The Biosimilar Red Tape Elimination Act, monitor legislation U.S. HOUSE OF REPRESENTATIVES, U.S. Senate, Natl Institutes of Health (NIH), Defense - Dept of (DOD), Food & Drug Administration (FDA), Veterans Affairs - Dept of (VA)","Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA)",,60810,0,0,2024-10-16T16:25:08-04:00
3241452,56c75e89-93bf-4c77-89f4-c64fb3b29166,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,AMERICAN SOCIETY FOR RADIATION ONCOLOGY,2024,third_quarter,MED,Discussions regarding patient access to radiation oncology.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",50000,,0,0,2024-10-16T16:59:54-04:00
3241741,0214a8ef-edde-45da-b9b3-e69e525464e4,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,BIONTECH US INC.,2024,third_quarter,MED,Educated policymakers on BioNTech's federally funded research and development activities.,"HOUSE OF REPRESENTATIVES,SENATE",110000,,0,0,2024-10-16T23:32:23-04:00
3241745,9b9522da-6200-4c67-9554-923905990fe4,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"LUMEN BIOSCIENCE, INC.",2024,third_quarter,MED,Educated policymakers and key government stakeholders on Lumens research and development activities in support of US Service members and Defense appropriations.,HOUSE OF REPRESENTATIVES,30000,,0,0,2024-10-16T23:43:51-04:00
3241820,fba8308b-a4ef-4f11-bb91-d9da1189f397,Q3,BALLARD PARTNERS,401104288,BRAIN ANEURYSM FOUNDATION,2024,third_quarter,MED,To promote and advocate for S. 895/HR. 902.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T07:29:27-04:00
3241876,b8dfe317-a1fb-4a51-898c-c4dce913abde,Q3,BALLARD PARTNERS,401104288,EXTHERA MEDICAL CORPORATION,2024,third_quarter,MED,Guidance and advocacy related to procurement approval from the VA and DoD health systems.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2024-10-17T08:46:00-04:00
3241879,48875e21-8ed8-4f19-98db-408853fa67d4,Q3,BALLARD PARTNERS,401104288,EXTREMITY CARE LLC,2024,third_quarter,MED,Promoting the advancement of healthcare technology.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",130000,,0,0,2024-10-17T08:54:56-04:00
3242138,81798433-6752-4449-ab3f-64d58a7b7a15,Q3,IPOLICY SOLUTIONS,401105127,ASSOCIATION FOR MOLECULAR PATHOLOGY,2024,third_quarter,MED,"No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Final Rule: Laboratory Developed Tests S.J.Res.82 - A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to ""Medical Devices; Laboratory Developed Tests""","HOUSE OF REPRESENTATIVES,SENATE",70500,,0,0,2024-10-17T10:14:36-04:00
3242310,e37b0962-b47e-4c5a-ae60-e6cc2eb6f436,Q3,THE CONSILIO GROUP,400374717,DETECTACHEM,2024,third_quarter,MED,Colorimetric explosive and narcotic detection capabilities,"Air Force, Dept of,Defense, Dept of (DOD),Education, Dept of,Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE,White House Office",16500,,0,0,2024-10-17T10:42:22-04:00
3242387,a4080582-4de7-42f5-9785-b4f199d9aa48,Q3,"COMMONWEALTH STRATEGIC PARTNERS, LLC",401103486,PEOPLE FOR THE ETHICAL TREATMENT OF ANIMALS (PETA),2024,third_quarter,MED,"Issues related to animal testing and experimentation, specifically H.R. 4757 Cease Animal Research Grants Overseas (CARGO) Act.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-17T10:49:33-04:00
3242405,9b053d0e-7605-4493-a0a2-808cc4e57d6b,Q3,"COMMONWEALTH STRATEGIC PARTNERS, LLC",401103486,AMERICAN ASSOCIATION OF SUICIDOLOGY,2024,third_quarter,MED,"Support policies and research for suicide awareness, training, outreach, and prevention, including but not limited to robust HHS funding and improvements to the 988 program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-17T10:50:37-04:00
3242491,23cc99e2-d1b0-40f4-8fb8-f96c9d1789c5,Q3,AMERICAN CLINICAL LABORATORY ASSN,1923,AMERICAN CLINICAL LABORATORY ASSN,2024,third_quarter,MED,"Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; FY 2024 budget and appropriations processes, artificial intelligence in laboratory services; public-private sector testing response in general and specific to Influenza A (H5) avian flu, monkeypox and oropouche; H.R. 2377/S. 1000, Saving Access to Laboratory Services Act; H.R. 8818, American Privacy Rights Act of 2024; H.R. 8702/S. 4532, Improving Seniors Timely Access to Care Act; and H.R. 2369, the Verifying Accurate Leading-edge IVCT Development Act (VALID Act) of 2023.","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Security Council (NSC),SENATE,White House Office",,540000,0,0,2024-10-17T11:00:12-04:00
3242525,dcc20774-85a6-4225-9ecb-0dc354ea9c2b,Q3,FONTENOT HEALTH POLICY LLC,401107703,ORGANIZE DBA ORGANIZE ACTION NETWORK,2024,third_quarter,MED,"Organ Procurement reforms; Revisions to the Outcome Measure Requirements for Organ Procurement Organizations; Final Rule (42 CFR, Part 486); Organ Procurement Organizations Conditions of Coverage; S. 1688/H.R. 2544 Securing the U.S. Organ Procurement and Transplantation Network Act","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T11:01:50-04:00
3242666,74277c65-ca95-4473-971b-3b5d5742607f,Q3,IMPACT HEALTH POLICY PARTNERS,401104696,ABBOTT LABORATORIES,2024,third_quarter,MED,"Issues related to coverage and reimbursement for durable medical equipment, medical devices, diagnostics and nutrition.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T11:13:24-04:00
3242703,679e795c-a211-44a9-9085-c795614592ce,Q3,IMPACT HEALTH POLICY PARTNERS,401104696,CHILDREN'S HOSPITAL COLORADO,2024,third_quarter,MED,Issues related to pediatric research and children's hospital graduate medical education.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2024-10-17T11:17:08-04:00
3242815,5134d2c5-1057-45ae-ae07-04c6c83bfaff,Q3,CAPITOL COUNSEL LLC,313715,"BLUE EARTH DIAGNOSTICS, INC.",2024,third_quarter,MED,To gain support for adequate Medicare reimbursement for diagnostic radiopharmaceuticals; H.R.1199 - Facilitating Innovative Nuclear Diagnostics Act of 2023.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2024-10-17T11:32:46-04:00
3243016,3330d236-72ee-43d9-aeaa-f30d435f26c7,Q3,"TENAGRITY SOLUTIONS, LLC",401107856,"KARDIOGENICS, INC.",2024,third_quarter,MED,Discussions with congressional offices and DoD re: client and how their product and work (including how they can help with defense); meetings with FDA officials re: approval for client's product,"Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-17T11:54:37-04:00
3243023,2d0d78e7-c653-4f44-bc03-b76d431b328b,Q3,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2024,third_quarter,MED,Issues regarding the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-17T11:56:09-04:00
3243039,00cf8694-aa39-4095-89a6-01345b583c08,Q3,CAPITOL COUNSEL LLC,313715,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2024,third_quarter,MED,Monitor health and tax legislation pertaining to the biotechnology industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T11:58:31-04:00
3243236,3be7e104-cb33-4233-9f61-1a7f07009b13,Q3,NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH,26557,NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH,2024,third_quarter,MED,Support funding for biomedical research,"HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2024-10-17T12:30:37-04:00
3243249,101d2563-b0db-46a5-bb61-b5419cb688d1,Q3,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2024,third_quarter,MED,Increasing funding for Myotonic Dystrophy research. Fiscal Year 2025 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-17T12:36:28-04:00
3243281,fcf6c1f9-b36e-46ee-bf2e-8352f31d6c8d,Q3,BLUEBIRD STRATEGIES,401105447,NCATS ALLIANCE,2024,third_quarter,MED,FY2025 NCATS funding,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2024-10-17T12:43:07-04:00
3243298,fc0e3b0e-3df5-4e67-9042-7e2e114539f8,3T,BLUEBIRD STRATEGIES,401105447,"MYRIAD GENETICS, INC.",2024,third_quarter,MED,Legislation to regulate clinical testing/labs.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2024-10-17T12:47:02-04:00
3243429,da94157a-cad7-487a-821c-035306e8c064,Q3,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2024,third_quarter,MED,Monitoring biotech legislation,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2024-10-17T13:13:43-04:00
3243907,76ffcd59-1cc0-45f8-8f41-ba44f6d7e5e6,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,VOCXI HEALTH,2024,third_quarter,MED,Educated policymakers and key government stakeholders on VOCxi Health research and development activities in support of US Service members and Defense appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T14:14:22-04:00
3243963,649b0dcf-a2ce-4083-8313-5425879d30e6,Q3,FORBES-TATE,400976792,AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION,2024,third_quarter,MED,Issues related to proposed cuts in the CY 2025 Medicare Physician Fee Schedule proposed rule; H.R. 2474 - Strengthening Medicare for Patients and Providers Act; H.R. 6371 - Provider Reimbursement Stability Act of 2023; S. 4935 - Physician Fee Stabilization Act.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-17T14:20:19-04:00
3244066,40ccf079-b8e8-4ac1-9581-f4caf7c10585,Q3,COVINGTON & BURLING LLP,11195,RWE ALLIANCE INC.,2024,third_quarter,MED,Real-world health data and analytics policy.,HOUSE OF REPRESENTATIVES,30000,,0,0,2024-10-17T14:26:46-04:00
3244231,2135d0ea-37ea-4b65-9a02-0feb6c2dd812,Q3,FORBES-TATE,400976792,"AMGEN USA, INC.",2024,third_quarter,MED,Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program.,"HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2024-10-17T14:39:04-04:00
3244280,e1508e4b-6cbd-43b5-bea7-c16e0545e712,Q3,"WILLIAMS AND JENSEN, PLLC",41454,RIVER REGION PSYCHIATRY ASSOCIATES,2024,third_quarter,MED,Work to educate Republican and Democrat members on the unique model of RRPA for providing psychiatric care and developing potential care pilot programs in Medicaid and/or CMMI.,"HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2024-10-17T14:46:03-04:00
3244432,0b7b8722-2560-48d1-b0b5-fa240334bcb6,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,THE REGENTS OF THE UNIVERSITY OF COLORADO OBO UNIVERSITY OF COLORADO ANSCHUTZ,2024,third_quarter,MED,Educated key government stakeholders on the University's medical capabilities in areas applicable to military health and readiness. Supported Defense authorizations and appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2024-10-17T14:56:48-04:00
3244537,3cfdca8b-b864-4d58-bfbb-ac0895e124cc,Q3,AMERICAN PHYSICAL THERAPY ASSOCIATION,3093,AMERICAN PHYSICAL THERAPY ASSOCIATION,2024,third_quarter,MED,"NIH Rehab issues APTA role with NIH Traumatic brain injury research Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions NIH Research and Development funding PT role in childhood obesity Relocate TBI State Grant Program to ACL NIDILRR - Rehab research Nomination to NIH Committees Safety of Children in School (Restraint & Seclusion) Falls and Falls Prevention","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,240412,0,0,2024-10-17T15:03:15-04:00
3244565,d9cf9457-b2d5-4000-90ec-275b35df483d,Q3,"TWENTY-FIRST CENTURY GROUP, INC.",38687,NRX PHARMACEUTICALS INC (FORMERLY KNOWN AS NEURORX),2024,third_quarter,MED,Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2024-10-17T15:06:34-04:00
3244689,cf11ab5c-24ec-4d99-bcb6-1a0c2d8e92cd,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,WASHINGTON STATE UNIVERSITY,2024,third_quarter,MED,"Educated key government stakeholders on WSU's research and development in support of US Service Members, support Defense appropriations and medical research programs for infectious diseases and global health within NIH","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2024-10-17T15:16:07-04:00